-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Initiates Coverage On Camp4 Therapeutics with Outperform Rating, Announces Price Target of $8

Benzinga·05/27/2025 11:21:58
Listen to the news
Wedbush analyst Yun Zhong initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform rating and announces Price Target of $8.